Program
leniolisib
Also written as “Leniolisib” and “CDZ173”.
Its studies are mostly in Common Variable Immunodeficiency · Primary Immunodeficiency Diseases · Lymphadenopathy, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pharming Group | 74 open or running | phase 3since Aug 4, 2016 | Aug 4, 2016 | Nov 30, 2026phase 3 · NCT05438407 |
| Novartis | 20 open or running | phase 3since Feb 24, 2015 | Feb 24, 2015 | none ahead |
Also a collaborator on its studies: aixial-group, cmic-co-ltd-japan, fortrea, laboratory-corporation-of-america and axial-biotech-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2015First study: phase 3 study in Common Variable ImmunodeficiencyNew to NovartisNovartis · NCT02435173 · 37 enrolled · United States, Belarus, Czechia and more
- May 16, 2016Phase 2 study in Primary Sjögren's SyndromeNovartis · NCT02775916 · 30 enrolled · Germany, Hungary
- Aug 4, 2016Pharming Group's first study: phase 3 study in Activated PI3K-delta SyndromeNew to Pharming GroupPharming Group · NCT02859727 · 37 enrolled · United States, Belarus, Czechia and more
- May 20, 2022Phase 3 study in APDSPharming Group · NCT05438407 · 15 enrolled · United States, France, Japan
- Oct 17, 2022Phase 3 study in APDSPharming Group · NCT05693129 · 16 enrolled · United States, Japan, Portugal and more
- Nov 21, 2023Phase 3 study in APDS Gene MutationPharming Group · NCT06249997 · 3 planned · Japan
- Jul 17, 2024Phase 2 study in Primary Immunodeficiency DiseasesPharming Group · NCT06549114 · 13 enrolled · United States
- Mar 12, 2025Phase 2 study in Common Variable ImmunodeficiencyPharming Group · NCT06897358 · 27 enrolled · United States, Spain, United Kingdom
- May 8, 2025Phase 2 study in PIDs Linked to PI3KPharming Group · NCT06990529 · 12 enrolled · United States, Spain, United Kingdom
Ahead
- Nov 30, 2026Primary completion: phase 3 study in APDSPharming Group · NCT05438407
- Jul 9, 2028Primary completion: phase 3 study in APDSPharming Group · NCT05693129
- Aug 12, 2029Primary completion: phase 2 study in PIDs Linked to PI3KPharming Group · NCT06990529
TargetBeta
“PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-delta subunit inhibitor”ChEMBL 37, by rule
Other programs on PIK3CD
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| idelalisibrule | Gilead Sciences | phase 4 | 28 |
| duvelisibrule | SecuraBio | phase 3 | 26 |
| gedatolisibrule | Pfizer | phase 3 | 9 |
| paxalisibrule | kazia-therapeutics-limited | phase 2 | 4 |
| roginolisibrule | ionctura | phase 2 | 4 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06990529PIDs Linked to PI3K · United States, Spain, United Kingdom | 2 | Active, not recruiting | Pharming Group | Aug 12, 2029 | 12 |
| NCT06897358Common Variable Immunodeficiency · United States, Spain, United Kingdom | 2 | Completed | Pharming Group | Aug 12, 2026 | 27 |
| NCT06549114Primary Immunodeficiency Diseases · United States | 2 | Completed | Pharming Group | Jun 23, 2026 | 13 |
| NCT06249997APDS Gene Mutation · Japan | 3 | Recruiting | Pharming Group | Jan 31, 2025 | 3 |
| NCT05693129APDS · United States, Japan, Portugal and more | 3 | Active, not recruiting | Pharming Group | Jul 9, 2028 | 16 |
| NCT05438407APDS · United States, France, Japan | 3 | Active, not recruiting | Pharming Group | Nov 30, 2026 | 15 |
| NCT02859727Activated PI3K-delta Syndrome · United States, Belarus, Czechia and more | 3 | Terminated | Pharming Group | Jan 30, 2025 | 37 |
| NCT02775916Primary Sjögren's Syndrome · Germany, Hungary | 2 | Completed | Novartis | May 17, 2017 | 30 |
| NCT02435173Common Variable Immunodeficiency · United States, Belarus, Czechia and more | 3 | Completed | Novartis | Aug 16, 2021 | 37 |
How it is read
Names in the registry
- “Leniolisib”, 6 entries
- “CDZ173”, 3 entries
Conditions, from the studies’ own filings
- Common Variable Immunodeficiency, 2 studies
- Primary Immunodeficiency Diseases, 1 study
- Lymphadenopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.